Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy

Table 3

Responses in treatmsent-naïve patients.

	Boceprevir (BOC)	Telaprevir (T)
	naïve	naïve
Overall rates, % (𝑛/𝑁)	SPRINT-2 [2]; BOC RGT + BOC/PR48 (ITT)	ADVANCE [3]; T12/PR24/48 + T8/PR24/48	ILLUMINATE [4]; T12/PR24 + T12/PR48 (ITT)
SVR	65 (475/734)	72 (521/727)	72 (388/540)
Relapse	9 (48/522)	9 (55/609)	8 (37/469)
Any adverse events, %	99	99	99
Rash	25	36	37
Anemia	49	38	39
Discontinuation due to adverse events	14	8^†	18

^†During telaprevir/placebo phase.
NA: not available; RGT: response-guided therapy; ITT: intention to treat.